{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:56:08Z","timestamp":1791219368530,"version":"4.1.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T00:00:00Z","timestamp":1719273600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T00:00:00Z","timestamp":1719273600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s11060-024-04716-0","type":"journal-article","created":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T08:01:47Z","timestamp":1719302507000},"page":"203-213","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["High-dose furmonertinib combined with intraventricular chemotherapy as salvage therapy for leptomeningeal metastasis from EGFR exon 20 insertion-mutated lung cancer"],"prefix":"10.1007","volume":"169","author":[{"given":"Chuanyong","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hehui","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangfeng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shencun","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,25]]},"reference":[{"key":"4716_CR1","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1016\/j.jtho.2016.06.029","volume":"11","author":"YS Li","year":"2016","unstructured":"Li YS, Jiang BY, Yang JJ, Tu HY, Zhou Q, Guo WB, Yan HH, Wu YL (2016) Leptomeningeal metastases in patients with NSCLC with EGFR mutations. J Thorac Oncol 11:1962\u20131969. https:\/\/doi.org\/10.1016\/j.jtho.2016.06.029","journal-title":"J Thorac Oncol"},{"key":"4716_CR2","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1097\/JTO.0000000000000669","volume":"10","author":"BC Liao","year":"2015","unstructured":"Liao BC, Lee JH, Lin CC, Chen YF, Chang CH, Ho CC, Shih JY, Yu CJ, Yang JC (2015) Epidermal growth factor receptor tyrosine kinase inhibitors for non-small-cell Lung Cancer patients with Leptomeningeal Carcinomatosis. J Thorac Oncol 10:1754\u20131761. https:\/\/doi.org\/10.1097\/JTO.0000000000000669","journal-title":"J Thorac Oncol"},{"key":"4716_CR3","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s40364-022-00372-6","volume":"10","author":"J Hou","year":"2022","unstructured":"Hou J, Li H, Ma S, He Z, Yang S, Hao L, Zhou H, Zhang Z, Han J, Wang L, Wang Q (2022) EGFR exon 20 insertion mutations in advanced non-small-cell lung cancer: current status and perspectives. Biomark Res 10:21. https:\/\/doi.org\/10.1186\/s40364-022-00372-6","journal-title":"Biomark Res"},{"key":"4716_CR4","doi-asserted-by":"publisher","first-page":"175883592211461","DOI":"10.1177\/17588359221146131","volume":"15","author":"JL Low","year":"2023","unstructured":"Low JL, Lim SM, Lee JB, Cho BC, Soo RA (2023) Advances in the management of non-small-cell lung cancer harbouring EGFR exon 20 insertion mutations. Ther Adv Med Oncol 15:17588359221146131. https:\/\/doi.org\/10.1177\/17588359221146131","journal-title":"Ther Adv Med Oncol"},{"key":"4716_CR5","doi-asserted-by":"publisher","first-page":"iv84","DOI":"10.1093\/annonc\/mdx221","volume":"28","author":"E Le Rhun","year":"2017","unstructured":"Le Rhun E, Weller M, Brandsma D, Van den Bent M, de Azambuja E, Henriksson R, Boulanger T, Peters S, Watts C, Wick W, Wesseling P, Ruda R, Preusser M, Board EE, Committee EG (2017) EANO-ESMO clinical practice guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours. Ann Oncol 28:iv84\u2013iv99. https:\/\/doi.org\/10.1093\/annonc\/mdx221","journal-title":"Ann Oncol"},{"key":"4716_CR6","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1016\/j.jtho.2019.07.031","volume":"14","author":"C Zhang","year":"2019","unstructured":"Zhang C, Zhang J, Xu FP, Wang YG, Xie Z, Su J, Dong S, Nie Q, Shao Y, Zhou Q, Yang JJ, Yang XN, Zhang XC, Li Z, Wu YL, Zhong WZ (2019) Genomic Landscape and Immune Microenvironment Features of Preinvasive and Early Invasive Lung Adenocarcinoma. J Thorac Oncol 14:1912\u20131923. https:\/\/doi.org\/10.1016\/j.jtho.2019.07.031","journal-title":"J Thorac Oncol"},{"key":"4716_CR7","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1093\/neuonc\/now183","volume":"19","author":"M Chamberlain","year":"2017","unstructured":"Chamberlain M, Junck L, Brandsma D, Soffietti R, Ruda R, Raizer J, Boogerd W, Taillibert S, Groves MD, Le Rhun E, Walker J, van den Bent M, Wen PY, Jaeckle KA (2017) Leptomeningeal metastases: a RANO proposal for response criteria. Neuro Oncol 19:484\u2013492. https:\/\/doi.org\/10.1093\/neuonc\/now183","journal-title":"Neuro Oncol"},{"key":"4716_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.lungcan.2022.09.013","volume":"174","author":"Y Wang","year":"2022","unstructured":"Wang Y, Yang X, Li NJ, Xue JX (2022) Leptomeningeal metastases in non-small cell lung cancer: diagnosis and treatment. Lung Cancer 174:1\u201313. https:\/\/doi.org\/10.1016\/j.lungcan.2022.09.013","journal-title":"Lung Cancer"},{"key":"4716_CR9","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.lungcan.2018.08.017","volume":"125","author":"Y Xu","year":"2018","unstructured":"Xu Y, Hu M, Zhang M, Zhong W, Yin X, Sun Y, Chen M, Zhao J, Si X, Wang H, Zhang X, Zhang L, Li J, Guan H, Yang Z, Wang M (2018) Prospective study revealed prognostic significance of responses in leptomeningeal metastasis and clinical value of cerebrospinal fluid-based liquid biopsy. Lung Cancer 125:142\u2013149. https:\/\/doi.org\/10.1016\/j.lungcan.2018.08.017","journal-title":"Lung Cancer"},{"key":"4716_CR10","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.lungcan.2012.03.002","volume":"77","author":"S Umemura","year":"2012","unstructured":"Umemura S, Tsubouchi K, Yoshioka H, Hotta K, Takigawa N, Fujiwara K, Horita N, Segawa Y, Hamada N, Takata I, Yamane H, Kamei H, Kiura K, Tanimoto M (2012) Clinical outcome in patients with leptomeningeal metastasis from non-small cell lung cancer: Okayama Lung Cancer Study Group. Lung Cancer 77:134\u2013139. https:\/\/doi.org\/10.1016\/j.lungcan.2012.03.002","journal-title":"Lung Cancer"},{"key":"4716_CR11","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1200\/JCO.19.00457","volume":"38","author":"JCH Yang","year":"2020","unstructured":"Yang JCH, Kim SW, Kim DW, Lee JS, Cho BC, Ahn JS, Lee DH, Kim TM, Goldman JW, Natale RB, Brown AP, Collins B, Chmielecki J, Vishwanathan K, Mendoza-Naranjo A, Ahn MJ (2020) Osimertinib in patients with epidermal growth factor receptor mutation-positive non-small-cell Lung Cancer and Leptomeningeal metastases: the BLOOM Study. J Clin Oncol 38:538\u2013547. https:\/\/doi.org\/10.1200\/JCO.19.00457","journal-title":"J Clin Oncol"},{"key":"4716_CR12","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.21037\/tlcr-20-382","volume":"9","author":"CW Xu","year":"2020","unstructured":"Xu CW, Wang WX, Wang D, Wang QM, Pu XX, Zhu YC, Huang JH, Yu ZY, Cui ZL, Chen XH, Li JL, Fang Y, Wang H, Zhuang W, Lan SJ, Cai X, Zhang YB, Gao WB, Wang LP, She KL, Rao CZ, Zhou YF, Fang MY, Miao LY, Lei L, Lv TF, Song Y (2020) Pemetrexed-based chemotherapy for non-small-cell lung cancer patients with EGFR exon 20 insertion mutation: a multicenter study. Transl Lung Cancer Res 9:1853\u20131861. https:\/\/doi.org\/10.21037\/tlcr-20-382","journal-title":"Transl Lung Cancer Res"},{"key":"4716_CR13","doi-asserted-by":"publisher","first-page":"1010311","DOI":"10.3389\/fonc.2022.1010311","volume":"12","author":"W Kian","year":"2022","unstructured":"Kian W, Christopoulos P, Remilah AA, Levison E, Dudnik E, Shalata W, Krayim B, Marei R, Yakobson A, Faehling M, Kahala D, Sara Granot I, Levitas D, Peled N, Roisman LC (2022) Real-world efficacy and safety of mobocertinib in EGFR exon 20 insertion-mutated lung cancer. Front Oncol 12:1010311. https:\/\/doi.org\/10.3389\/fonc.2022.1010311","journal-title":"Front Oncol"},{"key":"4716_CR14","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1002\/cam4.4852","volume":"12","author":"G Yang","year":"2023","unstructured":"Yang G, Yang Y, Liu R, Li W, Xu H, Hao X, Li J, Zhang S, Xu F, Lei S, Wang Y (2023) First-line immunotherapy or angiogenesis inhibitor combined with chemotherapy for advanced non-small cell lung cancer with EGFR exon 20 insertions: real-world evidence from China. Cancer Med 12:335\u2013344. https:\/\/doi.org\/10.1002\/cam4.4852","journal-title":"Cancer Med"},{"key":"4716_CR15","doi-asserted-by":"publisher","unstructured":"Cavaco M, Gaspar D, Arb Castanho M, Neves V (2020) Antibodies for the treatment of Brain metastases, a dream or a reality? Pharmaceutics 12. https:\/\/doi.org\/10.3390\/pharmaceutics12010062","DOI":"10.3390\/pharmaceutics12010062"},{"key":"4716_CR16","doi-asserted-by":"publisher","first-page":"3391","DOI":"10.1200\/JCO.21.00662","volume":"39","author":"K Park","year":"2021","unstructured":"Park K, Haura EB, Leighl NB, Mitchell P, Shu CA, Girard N, Viteri S, Han JY, Kim SW, Lee CK, Sabari JK, Spira AI, Yang TY, Kim DW, Lee KH, Sanborn RE, Trigo J, Goto K, Lee JS, Yang JC, Govindan R, Bauml JM, Garrido P, Krebs MG, Reckamp KL, Xie J, Curtin JC, Haddish-Berhane N, Roshak A, Millington D, Lorenzini P, Thayu M, Knoblauch RE, Cho BC (2021) Amivantamab in EGFR exon 20 insertion-mutated non-small-cell Lung Cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS phase I study. J Clin Oncol 39:3391\u20133402. https:\/\/doi.org\/10.1200\/JCO.21.00662","journal-title":"J Clin Oncol"},{"key":"4716_CR17","doi-asserted-by":"publisher","first-page":"e214761","DOI":"10.1001\/jamaoncol.2021.4761","volume":"7","author":"C Zhou","year":"2021","unstructured":"Zhou C, Ramalingam SS, Kim TM, Kim SW, Yang JC, Riely GJ, Mekhail T, Nguyen D, Garcia Campelo MR, Felip E, Vincent S, Jin S, Griffin C, Bunn V, Lin J, Lin HM, Mehta M, Janne PA (2021) Treatment outcomes and safety of Mobocertinib in platinum-pretreated patients with EGFR exon 20 insertion-positive metastatic non-small cell Lung Cancer: a phase 1\/2 Open-label Nonrandomized Clinical Trial. JAMA Oncol 7:e214761. https:\/\/doi.org\/10.1001\/jamaoncol.2021.4761","journal-title":"JAMA Oncol"},{"key":"4716_CR18","doi-asserted-by":"publisher","first-page":"100558","DOI":"10.1016\/j.jtocrr.2023.100558","volume":"4","author":"SI Ou","year":"2023","unstructured":"Ou SI, Lin HM, Hong JL, Yin Y, Jin S, Lin J, Mehta M, Nguyen D, Neal JW (2023) Real-world response and outcomes in patients with NSCLC with EGFR exon 20 insertion mutations. JTO Clin Res Rep 4:100558. https:\/\/doi.org\/10.1016\/j.jtocrr.2023.100558","journal-title":"JTO Clin Res Rep"},{"key":"4716_CR19","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/s12885-023-10676-x","volume":"23","author":"Z Xu","year":"2023","unstructured":"Xu Z, Hao X, Wang Q, Yang K, Li J, Xing P (2023) Intracranial efficacy and safety of furmonertinib 160\u00a0mg with or without anti-angiogenic agent in advanced NSCLC patients with BM\/LM as salvage therapy. BMC Cancer 23:206. https:\/\/doi.org\/10.1186\/s12885-023-10676-x","journal-title":"BMC Cancer"},{"key":"4716_CR20","doi-asserted-by":"crossref","unstructured":"Han B, Wu CZL, Yu X, Li Q, Liu F, Shen C (2021) Preclinical and preliminary clinical investigations of furmonertinib in NSCLC with EGFR exon 20 insertions (20ins). Annals of Oncology. p S964","DOI":"10.1016\/j.annonc.2021.08.1815"},{"key":"4716_CR21","doi-asserted-by":"publisher","first-page":"7729","DOI":"10.1007\/s00432-023-04726-x","volume":"149","author":"H Sa","year":"2023","unstructured":"Sa H, Shi Y, Ding C, Ma K (2023) A real-world study of the efficacy and safety of furmonertinib for patients with non-small cell lung cancer with EGFR exon 20 insertion mutations. J Cancer Res Clin Oncol 149:7729\u20137742. https:\/\/doi.org\/10.1007\/s00432-023-04726-x","journal-title":"J Cancer Res Clin Oncol"},{"key":"4716_CR22","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1056\/NEJM197507242930402","volume":"293","author":"WR Shapiro","year":"1975","unstructured":"Shapiro WR, Young DF, Mehta BM (1975) Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. N Engl J Med 293:161\u2013166. https:\/\/doi.org\/10.1056\/NEJM197507242930402","journal-title":"N Engl J Med"},{"key":"4716_CR23","doi-asserted-by":"publisher","DOI":"10.3340\/jkns.2023.0178","author":"SM Jang","year":"2023","unstructured":"Jang SM, Gwak HS, Kwon JW, Shin SH, Yoo H (2023) Clinical safety and efficiency of the H-Port for treatment of Leptomeningeal Metastasis. J Korean Neurosurg Soc. https:\/\/doi.org\/10.3340\/jkns.2023.0178","journal-title":"J Korean Neurosurg Soc"},{"key":"4716_CR24","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1634\/theoncologist.2014-0199","volume":"19","author":"HS Gwak","year":"2014","unstructured":"Gwak HS, Joo J, Shin SH, Yoo H, Han JY, Kim HT, Yun T, Ro J, Lee JS, Lee SH (2014) Ventriculolumbar perfusion chemotherapy with methotrexate for treating leptomeningeal carcinomatosis: a phase II study. Oncologist 19:1044\u20131045. https:\/\/doi.org\/10.1634\/theoncologist.2014-0199","journal-title":"Oncologist"},{"key":"4716_CR25","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-024-04653-9","author":"A Gaietto","year":"2024","unstructured":"Gaietto A, Panetta JC, Pauley JL, Relling MV, Ribeiro R, Ehrhardt MJ, Pui CH, Inaba H, Swanson HD (2024) Ommaya reservoir use in pediatric ALL and NHL: a review at St. Jude Children\u2019s Research Hospital. Cancer Chemother Pharmacol. https:\/\/doi.org\/10.1007\/s00280-024-04653-9","journal-title":"Cancer Chemother Pharmacol"},{"key":"4716_CR26","doi-asserted-by":"publisher","first-page":"509","DOI":"10.3389\/fonc.2018.00509","volume":"8","author":"M Montes de Oca Delgado","year":"2018","unstructured":"Montes de Oca Delgado M, Cacho Diaz B, Santos Zambrano J, Guerrero Juarez V, Lopez Martinez MS, Castro Martinez E, Avendano Mendez-Padilla J, Mejia Perez S, Reyes Moreno I, Gutierrez Aceves A, Gonzalez Aguilar A (2018) The Comparative Treatment of Intraventricular Chemotherapy by Ommaya Reservoir vs. lumbar puncture in patients with Leptomeningeal Carcinomatosis. Front Oncol 8:509. https:\/\/doi.org\/10.3389\/fonc.2018.00509","journal-title":"Front Oncol"},{"key":"4716_CR27","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1097\/JTO.0b013e318287c943","volume":"8","author":"HS Gwak","year":"2013","unstructured":"Gwak HS, Joo J, Kim S, Yoo H, Shin SH, Han JY, Kim HT, Lee JS, Lee SH (2013) Analysis of treatment outcomes of intraventricular chemotherapy in 105 patients for leptomeningeal carcinomatosis from non-small-cell lung cancer. J Thorac Oncol 8:599\u2013605. https:\/\/doi.org\/10.1097\/JTO.0b013e318287c943","journal-title":"J Thorac Oncol"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-024-04716-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-024-04716-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-024-04716-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T06:17:55Z","timestamp":1721801875000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-024-04716-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,25]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["4716"],"URL":"https:\/\/doi.org\/10.1007\/s11060-024-04716-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4301016\/v1","asserted-by":"object"}]},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,25]]},"assertion":[{"value":"21 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of the Nanjing Chest Hospital (2023-KL023-02).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from all participants before enrolment.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}